PerkinElmer has acquired biotechnology company Covaris, in a move that PerkinElmer said will expand its existing life sciences portfolio into the high-growth diagnostics end market. Covaris is a developer of high-throughput genomic and proteomic analysis instruments, consumables, and reagents. Its solutions aim to enable research and drug discovery for clinical diagnostics, biopharma, and research markets globally. Terms of the transaction were not disclosed. According to Andre Moura, managing director at New Mountain Capital, majority owner of both companies, Covaris’ strong position in genomics, transcriptomics, and proteomics brings a growth vector to PerkinElmer. The acquisition comes after Revvity Inc., a science-based solutions company that formerly functioned as the life sciences business of PerkinElmer, launched in May. Revvity has retained certain franchises that once operated under the PerkinElmer umbrella, including BioLegend.